Over 55,000 South Africans Start New Twice-Yearly HIV Prevention Treatment
Since its national launch in June, more than 55,000 people in South Africa have begun using lenacapavir. This new medical treatment is an injectable medicine designed to prevent HIV infection. Unlike daily pills, patients only need to receive this injection twice a year, making it a significant development in public health.
Data shows that women make up 71% of the new users. Health experts suggest that this high participation rate among women is due to the convenience and privacy that the twice-yearly injection offers. By reducing the need for daily medication, the treatment helps individuals manage their health more easily while maintaining their personal routines.
The introduction of lenacapavir is part of South Africa’s ongoing efforts to lower HIV transmission rates across the country. The government and health organizations have been working to make this preventative option available to as many people as possible. By providing a long-acting alternative, officials hope to increase the number of people who can effectively protect themselves from the virus.
Medical professionals continue to monitor the rollout of the injection to ensure it remains accessible to those who need it most. As the program grows, health authorities are focusing on education and awareness to help more South Africans understand the benefits of this new prevention tool. This initiative marks a major step forward in the national strategy to address HIV in South Africa.